BioWorld

July 16, 2003

MIT Scientist Rejects Mutagenic Cause of Neoplasms; Espouses Outside Factors Over Mutations

Industry Reps Continue Debating The Issue Of Generic Biologics

Several Hybridon Presentations Highlight Early Cancer Platform

Other News To Note

Trimeris, Roche Increase Capacity For Fuzeon, Release More Data

Reports of increased global supplies of Fuzeon, coupled with longer-term data on the product, gave Trimeris Inc. a boost from investors eyeing higher earnings from early sales of the FDA-approved HIV drug. (BioWorld Today) Read More

Medivir, Boehringer Ingelheim Enter Potential EUR122M Alliance

NIH changes set industry up for workforce, ideas drought

BioWorld

On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...

Today's news in brief

BioWorld

BioWorld briefs for March 6, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 6, 2025

Roche looks to grow with sequencing by expansion tech

BioWorld MedTech

Roche Holding AG revealed plans to launch its sequencing by expansion technology next year, raising the possibility that rival Illumina Inc. could face a real run...

Illustration of Magnet Biomedicine's Trueglue platform

Magnet, Eli Lilly sign $1.25B molecular glue deal for oncology

BioWorld

About 17 months after emerging from stealth with its Trueglue discovery platform, Magnet Biomedicine Inc. has joined with Eli Lilly and Co. to discover, develop...